On the leading edge of Personalized Medicine, Big Data Analytics and BioPharmaceutical R&D for >20 years, Iris is the Chief Therapeutics Officer of Eleven Therapeutics, where she oversees the strategy and development of novel RNA-based therapeutics discovered by the company’s platform, which uniquely marries between combinatorial chemistry and A.I. to decipher the structure-activity relationship of durable, effective and safe respiratory and metabolic therapeutics. Prior to joining Eleven, Iris served in Chief Scientific Officer roles (CAMP4, Amide Technologies (acting)) and consulted for top VCs in the Boston area. Prior to that, Iris held leadership positions in, or consulted for Big Pharma (GSK, Eli Lily, Takeda and Teva – where she was VP, Head of Early-Stage Development). She specializes in leveraging multi-dimensional genomic insights and eHealth as engines of therapeutic discovery, development and lifecycle management across a wide range of modalities and therapeutic areas.

Dr. Grossman serves as Chairman of the Pharma/Life Sciences SAB at BC Platforms, and as Strategic Founding Advisor at Modulight.bio, and CGRP Diagnostics. She was a pioneering Steering Committee member of Tipa (Maccabi biobank) and is an active member and strategic advisor to the 8400 Healthcare network. Iris has championed various multi-year, multi-million dollars partnerships and collaborations, as well as won multiple awards, throughout her career, including the prestigious Top 40 under 40 award (2013) by Globes – Israel’s business arena, and various recognition awards for contributions to R&D programs and cutting edge science.

Dr. Grossman earned her BSc in medicine at the Technion, and a Ph.D. in medicine, population genomics and pharmacogenetics from the Technion, co-mentored with the Weizmann Institute. Her post-doc fellowship in Personalized Medicine and Population Genomics was completed at Duke university. She recently completed a Harvard Business School Executive HealthTech program.